Sclerotherapy for hydrocele and epididymal cysts: a five year study
The treatment of hydroceles by injecting various agents has been used intermittently over several centuries,' Nevertheless, surgery is now recommended as the definitive treatment. The reason injection treatment has fallen out of favour is not clear but such neglect appears to be based on poor evidence.2 The early results of a prospective study of sclerotherapy for hydrocele and epididymal cysts were presented in 19793; this paper reviews the results five years after treatment.
Patients, methods, and results
Seventy symptomatic patients (mean age 63, range with one or more hydrocele or epididymal cysts were included in the study (those who had an ipsilateral inguinal hernia were rejected). Some 14 patients had to be excluded as they did not complete the course of treatment; six required surgery as there was a bloodstained tap or the lump did not transilluminate; five failed to attend follow up appointments; and three died of unrelated causes. The 56 remaining patients had 49 hydroceles and 14 epididymal cysts. The method of treatment3 was, in summary, to transilluminate the scrotum to confirm the diagnosis and identify the testis. A size 18 gauge Medicut was then inserted into the upper border of the hydrocele or cyst under local anaesthesia. The Medicut was used because a plastic cannula is less likely to damage the lining of the sac and is unlikely to slip out when the operator is aspirating fluid or injecting sclerosant. The fluid was completely aspirated and its volume measured. The sclerosant (2-5% phenol in water) was then injected: 5 ml into a sac containing less than 50 ml of fluid, 10 ml for 51-200 ml; 15 ml for 201-400 ml; and 20 ml for over 400 ml. The patients were seen every six weeks and the treatment repeated until no fluid reaccumulated.
All 49 hydroceles and 14 epididymal cysts were successfully treated ( (table) , but only one (of 100 ml in what had originally been 270 ml) was noticed by the patient.
Comment
The early results of this study confirmed the efficacy of this method of treatment.4 Recently Macfarlane using a different sclerosant has reported equally good early results.5 The three early recurrences were successfully retreated and had not recurred at the five year review. Three of the patients with late recurrences were asymptomatic and did not require further treatment, leaving a symptomatic recurrence rate of 30, for hydroceles. The testicular pain after injection of the phenol is mild and may be avoided by injecting a small quantity of local anaesthetic into the sac before the phenol. None of the complications resulted in hospital admission. Residual epididymal or testicular thickening after treatment of the larger hydroceles is not surprising in view of the size of the tunica vaginalis. Nevertheless, the end result was always acceptable to the patient given the appreciable reduction in the size of the swelling. The Reversal with balsalazide of infertility caused by sulphasalazine Sulphasalazine is commonly used to maintain remission in ulcerative colitis but has many toxic side effects including infertility in men.
Compounds of the drug have been designed without the sulphonamide moiety, which is thought to be the specifically toxic factor. We used one of these new compounds, balsalazide (5-(carboxy ethylcarbamoyl-4-phenylazo)-salicylic acid), to treat three young men who presented with infertility induced by sulphasalazine. We report here the results.
Patients, methods, and results
Three men with ulcerative colitis, in whom remission of disease was maintained with sulphasalazine 2-3 g daily, presented with infertility. Two had a history of relapse after stopping sulphasalazine and had subsequently taken the drug for nine and 12 months respectively. The third had not experimented with withdrawal of treatment and had taken sulphasalazine continually for five years. Two had fathered children before receiving sulphasalazine. After giving informed consent the patients received balsalazide 2 g daily for four months. They were asked to provide semen specimens before and at monthly intervals during treatment; the numbers and motility of their sperms were determined. Full blood counts, serum biochemical tests, and urine microscopy were performed monthly. Clinical examination and sigmoidoscopy were used to monitor the patients' colitis, and rectal mucosal biopsies were undertaken before and after treatment.
Remission (years)  1  2  3  4  1  2  3  4   1  32  22  25  25  54  60  20  70  70  70  70  2  36  10  10  30  30  40  10  20  50  50  50  3*  30  20 *No specimen received during treatment; wife became pregnant in third month.
any side effects from balsalazide. There were no abnormalities of haemoglobin concentration, white cell and platelet counts, liver function, or serum electrolyte concentrations. Urine microscopy yielded normal results on all occasions.
Comment
In about 65%1 of patients with ulcerative colitis remission may be maintained with sulphasalazine 2 g daily for at least a year.' Colonic bacteria split the sulphasalazine molecule into 5-aminosalicylic acid and sulphapyridine. The active moiety, 5-aminosalicylic acid,2 is excreted mainly in the faeces. Sulphapyridine is absorbed into the blood and probably causes the nausea, headaches, and rashes that preclude the use of sulphasalazine in about 10%// of patients. Infertility with oligospermia has also been reported in men receiving sulphasalazine for over two months3 and has been shown to be caused by sulphapyridine.4 Substituting an inert, non-absorbed carriei molecule for sulphapyridine could theoretically reduce side effects while maintaining the anti-inflammatory action of 5-aminosalicylic acid. With this aim balsalazide was synthesised by linking 5-aminosalicylic acid and 4-aminobenzylalanine.5
After four months' treatment with balsalazide 2 g daily sperm count and motility had definitely returned to normal in two of our patients and had probably done so in the third as inferred from the pregnancy of his wife. Remission of ulcerative colitis was maintained satisfactorily in all three. Balsalazide may be an important new drug for the treatment of young men with ulcerative colitis and an alternative in patients who develop side effects to sulphasalazine. 
